AlphaQuest LLC Buys 23,974 Shares of Capricor Therapeutics, Inc. $CAPR

AlphaQuest LLC lifted its position in Capricor Therapeutics, Inc. (NASDAQ:CAPR) by 396.2% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 30,025 shares of the biotechnology company’s stock after purchasing an additional 23,974 shares during the quarter. AlphaQuest LLC owned 0.07% of Capricor Therapeutics worth $216,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the company. Farther Finance Advisors LLC bought a new stake in Capricor Therapeutics during the third quarter worth about $28,000. Parkside Financial Bank & Trust acquired a new position in shares of Capricor Therapeutics in the 3rd quarter worth approximately $36,000. Tower Research Capital LLC TRC grew its position in Capricor Therapeutics by 280.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company’s stock worth $67,000 after acquiring an additional 4,976 shares during the last quarter. Sheets Smith Investment Management acquired a new stake in Capricor Therapeutics during the 3rd quarter valued at $107,000. Finally, KLP Kapitalforvaltning AS increased its holdings in Capricor Therapeutics by 65.2% during the 2nd quarter. KLP Kapitalforvaltning AS now owns 10,900 shares of the biotechnology company’s stock valued at $108,000 after purchasing an additional 4,300 shares in the last quarter. 21.68% of the stock is owned by institutional investors.

Capricor Therapeutics Stock Down 2.2%

NASDAQ:CAPR opened at $24.63 on Wednesday. Capricor Therapeutics, Inc. has a 12-month low of $4.30 and a 12-month high of $40.37. The stock’s fifty day simple moving average is $25.94 and its 200-day simple moving average is $13.43. The firm has a market capitalization of $1.13 billion, a P/E ratio of -13.68 and a beta of 0.38.

Capricor Therapeutics (NASDAQ:CAPR) last released its earnings results on Monday, November 10th. The biotechnology company reported ($0.54) earnings per share for the quarter, meeting the consensus estimate of ($0.54). As a group, equities research analysts expect that Capricor Therapeutics, Inc. will post -1.21 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently commented on the company. Oppenheimer increased their target price on Capricor Therapeutics from $22.00 to $54.00 and gave the stock an “outperform” rating in a report on Monday, December 8th. Piper Sandler reiterated an “overweight” rating and set a $45.00 price target (up previously from $20.00) on shares of Capricor Therapeutics in a research report on Wednesday, December 10th. B. Riley Financial restated a “buy” rating and issued a $50.00 price objective (up previously from $21.00) on shares of Capricor Therapeutics in a research report on Monday, December 15th. Wall Street Zen downgraded shares of Capricor Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, January 11th. Finally, iA Financial set a $48.00 target price on shares of Capricor Therapeutics in a research report on Wednesday, December 3rd. Nine research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Capricor Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $40.82.

Capricor Therapeutics Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.